Causeway Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $3.09M

  • Investors
  • 8

Causeway Therapeutics General Information

Description

Developer of novel microRNA therapies designed to treat common musculoskeletal diseases. The company develops therapies that are based on identifying the molecular mechanism that causes damaged tendons to develop tendinopathy caused by loss of microRNA and controls the repair process by their pharmaceutical product that mimics this natural microRNA and cures them, enabling patients to reduce the pain of damaged and weakened tendons in a faster and advanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Imaging Centre of Excellence Building
  • Queen Elizabeth University Hospital
  • Glasgow G51 4TF
  • Scotland, United Kingdom
+44 0141
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Imaging Centre of Excellence Building
  • Queen Elizabeth University Hospital
  • Glasgow G51 4TF
  • Scotland, United Kingdom
+44 0141

Causeway Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Causeway Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 25-Jul-2025 $3.09M Completed Generating Revenue
7. Later Stage VC 27-Feb-2023 Completed Clinical Trials - Phase 2
6. Grant 01-Jun-2020 Completed Clinical Trials - Phase 1
5. Grant 01-Feb-2019 Completed Clinical Trials - Phase 1
4. Early Stage VC 19-Jun-2018 Completed Clinical Trials - Phase 1
3. Grant 31-May-2018 Completed Clinical Trials - Phase 1
2. Seed Round 03-Aug-2017 $1.3M $1.3M Completed Clinical Trials - Phase 1
1. University Spin-Out 20-Oct-2015 Completed Startup
To view Causeway Therapeutics’s complete valuation and funding history, request access »

Causeway Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred Series 2
Preferred Series 2
Preferred Series 2
Preferred Series 2
Preferrence 500,000 $0.000136 $2.71 $2.71 1x $2.71 10.43%
Preferrence 640,000 $0.000136 $2.12 $2.12 1x $2.12 13.35%
To view Causeway Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Causeway Therapeutics Patents

Causeway Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023445724-A1 Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions Pending 28-Apr-2023
US-20240360446-A1 Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions Pending 28-Apr-2023
WO-2024223065-A1 Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions Inactive 28-Apr-2023
AU-2021365394-A1 Microrna-29 compounds, compositions and uses in therapy Pending 23-Oct-2020
AU-2021365394-A9 Microrna-29 compounds, compositions and uses in therapy Pending 23-Oct-2020
To view Causeway Therapeutics’s complete patent history, request access »

Causeway Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Causeway Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
GU Holdings Holding Company Minority
Rahn+Bodmer Asset Manager Minority
Angel (individual) Minority
University of Glasgow Endowment Limited Partner Minority
Innovate UK Government
You’re viewing 5 of 8 investors. Get the full list »

Causeway Therapeutics FAQs

  • When was Causeway Therapeutics founded?

    Causeway Therapeutics was founded in 2015.

  • Where is Causeway Therapeutics headquartered?

    Causeway Therapeutics is headquartered in Glasgow, United Kingdom.

  • What is the size of Causeway Therapeutics?

    Causeway Therapeutics has 7 total employees.

  • What industry is Causeway Therapeutics in?

    Causeway Therapeutics’s primary industry is Drug Discovery.

  • Is Causeway Therapeutics a private or public company?

    Causeway Therapeutics is a Private company.

  • What is the current valuation of Causeway Therapeutics?

    The current valuation of Causeway Therapeutics is .

  • What is Causeway Therapeutics’s current revenue?

    The current revenue for Causeway Therapeutics is .

  • How much funding has Causeway Therapeutics raised over time?

    Causeway Therapeutics has raised $23M.

  • Who are Causeway Therapeutics’s investors?

    GU Holdings, Rahn+Bodmer, , University of Glasgow Endowment, and Innovate UK are 5 of 8 investors who have invested in Causeway Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process